Treatment of inappropriate secretion of thyrotropin with somatostatin analog SMS 201-995.
Inappropriate thyrotropin secretion (IST) may originate from either neoplastic disease (nIST) or non-neoplastic resistance to thyroid hormone (nnIST). An inhibitory effect of somatostatin on TSH secretion has been documented. In an attempt to elucidate the possible therapeutic effect of this peptide on nIST and nnIST, a study was conducted in 7 such patients. Sandostatin (SMS 201-995) was administered in daily doses of 100 micrograms for several days to 1 month. Four patients with nIST responded with a fall in circulating TSH as well as alpha-subunit with concomitant normalization of free thyroxine and clear symptomatic improvement. In the 3 nnIST patients this effect was considerably less apparent and a partial TSH escape was observed on long-term treatment in 2 cases. The importance of somatostatin and its analogs in the management of thyroid malignancy is stressed.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015282:Octreotide; D010900:Pituitary Diseases / Q000188:drug therapy*; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*; D014284:Triiodothyronine / Q000097:blood
D000970:Antineoplastic Agents; D014284:Triiodothyronine; D013004:Somatostatin; D013972:Thyrotropin; D015282:Octreotide